Levilimab vs placebo or usual care
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
Levilimab may leads to higher clinical improvement D28b compared with standard care/placebo (low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 1.53 [1.26, 1.85]1 study · 206 participantsLow